18th Pharmacovigilance 2019

From Verify.Wiki
Jump to: navigation, search
Wizard photo 18th Pharmacovigilance 2019 1.jpg
18th Pharmacovigilance 2019
Date 2019-02-27
Place 27th & 28th February 2019

Pestana Chelsea Bridge Hotel 354 Queenstown Rd, London SW8 4AE

18th Annual Pharmacovigilance 2019 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organizations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pharmacovigilance requirements, and to improve their organization’s compliance with pharmacovigilance requirements. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development.

CONFERENCE INTRODUCTION:-

Global pharmacovigilance market is expected to reach USD 5.51 billion by 2020, according to a new study by Grand View Research, Inc. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key drivers of this market. ADR is responsible for approximately 5% of the hospitalization in developed countries annually, and this is expected to boost usage rates over the next six years. Pharmacovigilance has witnessed a significant rise in usage rates in the recent times owing to growing global geriatric population triggering a growth in demand for new drug development. Additionally, health regulatory authorities such as the U.S. FDA and EMEA (European Medicines Agency) are now emphasizing on electronic submission of data which is also expected to drive the pharmacovigilance market.

BREXIT’s another big issue is medicines. Every month the UK exports 45 million packs of medicines to the EU and EEA countries, and imports more than 37 million. Again, prolonged disruption at borders could threaten supplies of drugs and other vital healthcare products – both in the UK and elsewhere in Europe. There is more scope with medicines than with food to increase stocks of things like tablets, but other imported drugs such as insulin often need to be refrigerated and may therefore pose bigger logistical challenges.

18th Annual Pharmacovigilance 2019 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organisations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pharmacovigilance requirements, and to improve their organisations' compliance with pharmacovigilance requirements. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development.

It gives me great pleasure in welcoming all of you to the Virtue Insight’s 18th Pharmacovigilance 2019. I wish and pray that all our efforts will be beneficial to our industries and to our country at large.


Top Photos

Top Videos

Speaker Highlights

·         JACKIE ROBERTS, Executive Director Regulatory, Pharmacovigilance and Medical / QPPV, Accord Healthcare

·         JABEEN AHMAD, Regional PV Director, EEMEA, Abbvie

·         SUSAN WELSH, Chief Safety Officer, CSL Behring (USA)

·         RICARDA TIEMEYER, Head of Drug Safety & PoC Medical Information, Roche

·         PAOLO VOLTOLINA, Associate Director Regulatory Affairs, CSL Behring

·         MIROSLAVA NOVAKOVA, Medical Advisor, Sanofi Pasteur (Slovak Republic)

·         YUUNG YUUNG YAP, Senior International Regulatory Counsel, EU and International Regulatory Law, Pfizer

·         DAVID JEFFERYS, Sr. VP Regulatory, Eisai

·         TANJA PETERS, Global Head of PV Intelligence, Deputy EU QPPV, Boehringer Ingelheim

·         JOHN SOLOMON, Head of Pharmacovigilance - UK & Ireland, Sanofi

·         SUMIT MUNJAL, Global Director, Pharmacovigilance & EU Region Medical Advisor - Lead Oncology Portfolio, Takeda Pharmaceuticals

·         MICHAEL BEAN, Senior Director, Regulatory Compliance R&D, Johnson & Johnson

·         STEINAR MADSEN, Medical Director, Norweigen Medicines Agency

·         PAUL WANG, Director, Safety Science, Kite Pharma (USA)

·         DORIS STENVER, Chief Medical Officer, Member of the Pharmacovigilance Risk Assessment Committee (PRAC), Danish Medicines Agency

·         ALEJANDRA PADOVANI, Safety Scientist, Roche

·         SABINE POLTERMANN, Head Scientific Product Information, Novartis

·         HEINZ WEIDENTHALER, Director Pharmacovigilance, QPPV, Bavarian Nordic

·         MIRCEA CIUCA, Global Head Medical & Clinical Drug Safety, Vifor Pharma

·         FRANCK SCHWARTZ, QA Global Inspection, Intelligence Lead - Compliance and Regulatory Affairs, Novartis

·         ALINA TUDOR, Associate Director, Senior PV Physician/Deputy EUQPPV, Norgine

·         RAJ BHOGAL, Safety & International Director, Regulatory Inspections, R&D QA&C, Shire Pharmaceuticals

Key Themes

·         Brexit Implications for the UK Pharmaceutical (pharmacovigilance) Industry

·         What would 'no deal' mean for medicine?

·         New Technologies in Pharmacovigilance (AI/ Machine Learning, IoT)

·         Quality, Safety and Signal Detection - Future of 2020 

·         PV Audit & Inspections – Knowing what is to be done

·         Drug safety work in the pre-clinical/clinical transition and early clinical development phase

·         Pharmacovigilance in 2020 - future horizons and efficiencies

·         Updates towards of legislation, policies, systems, technology, communication strategies and best practice in PV

·         Possible effects of Brexit on Pharmacovigilance

·         Benefit/Risk ratio: the common denominator

·         Market analysis – What is our current stand? – Moving towards the new successful PV era

·         PV – Risk Management and Planning

·         Risk management in the lifecycle of a drug

·         Examining developments in GVP measures and status of the new Module VI

·         Improving in signal management and their implications

·         Latest updates and hot topics relating to the role of the QPPV

·         Challenges and Opportunities to optimize the overall PV ecosystem for maximum benefit

·         Quality, Safety and Signal Detection - Future of 2020 

·         Medical devices – Increasing safety perspective

·         Case studies from various countries on the PV frameworks around the world

·         Good Clinical Practices and Good Pharmacovigilance practices

·         Proper communication - Sponsor – Site – CRO & Patients

·         Patient centric approach to help improve patient safety

·         Outsourcing activities - How to set it right?

·         How to involve patients better to develop drugs

·         The developing regulatory framework in advanced and developing markets – EU, USA & ROW

·         Accelerating new medicine introduction in developing world & overcoming challenges

·         Be part of a major networking opportunity

Who Should Attend

CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:

Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales and Marketing

Conference Sponsorship

Email: kavitha@virtueinsight.co.in  or TEL: +44 2036120886

Sponsor, Exhibition Stall (Booth) and a paid Speaker Slots are also available

We also have some sponsorship opportunities available for the event, which gives you an opportunity to sponsor/speak/exhibit, and create brand awareness. In addition, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts.

CONFERENCE REGISTRATION:

Email: kavitha@virtueinsight.co.in  or TEL: +44 2036120886

·         Introductory Offer (3 delegate places for the price of 2) - A huge saving discount and only Limited seats left.

·         Early Bird Discount (Ends 24th January 2019): Conference Delegate Pass (£950 + VAT per delegate)

·         Standard Registration (From 25th January 2019): Conference Delegate Pass (£1150 + VAT per delegate)

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

Verification history